Company to host conference call on Tuesday, June 25, 2019 at 1:30
p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on
its clinical and preclinical programs
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced the Company will be presenting preliminary data from the
ongoing Phase 1 dose-escalation trials of AB928, a potential
best-in-class dual A2a/A2b receptor antagonist, in
a poster session at the 2019 American Society of Clinical Oncology
(ASCO) Annual Meeting taking place in Chicago, IL, from May 31-June 4,
2019.
Poster presentation details
Abstract Title: AB928, a Novel Dual Adenosine Antagonist,
Combined With Chemotherapy or AB122 (anti-PD-1) in Patients With
Advanced Tumors: Preliminary Results From Ongoing Phase 1 Studies
Abstract
Number: 2604
Session Information: Developmental
Immunotherapy and Tumor Immunobiology
Date and Time: Saturday,
June 1, 8:00 a.m. - 11:00 a.m. Central Time
Location: Hall
A
A copy of the poster will be available on the “Publications” section of
the Arcus website at www.arcusbio.com.
Conference call details
Arcus will host a conference call and live webcast on Tuesday, June 25,
2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a
mid-year update on its clinical and preclinical programs. Investors
interested in listening to the conference call may do so by dialing
(866) 211-3164 in the U.S. or (647) 689-6573 internationally, using
Conference ID: 7163128. In addition, the live webcast and accompanying
slides will be available on the “Investors” section of the Arcus website
at www.arcusbio.com.
Following the live webcast, a replay will be available on the Company’s
website for approximately 30 days.
About AB928
AB928 is an orally bioavailable, highly potent antagonist of the
adenosine 2a and 2b receptors. The activation of these receptors by
adenosine interferes with the activity of key populations of immune
cells and inhibits an optimal anti-tumor immune response. By blocking
these receptors, AB928 has the potential to reverse adenosine-induced
immune suppression within the tumor microenvironment. AB928 was designed
specifically for the oncology setting, with a profile that includes
potent activity in the presence of high concentrations of adenosine and
a minimal shift in potency due to non-specific protein binding, both
essential properties for efficacy in the tumor microenvironment. AB928
has other attractive features, including high penetration of tumor
tissue and low penetration through the healthy blood-brain barrier. In a
Phase 1 trial in healthy volunteers, AB928 has been shown to be safe and
well tolerated and to have pharmacokinetic and pharmacodynamic profiles
consistent with a once-daily dosing regimen.
About AB122
AB122 is a fully human IgG4 antibody that potently and selectively
blocks PD-1. The biochemical, biological and preclinical properties of
AB122 have been shown to be similar to those of the marketed anti-PD-1
antibodies nivolumab and pembrolizumab. AB122 is being evaluated in
ongoing Phase 1/1b dose-escalation and dose-expansion trials evaluating
AB122 in combination with AB928, a potential best-in-class dual A2a/A2b
receptor antagonist, and in combination with AB154, a potential
best-in-class anti-TIGIT antibody. In May 2019, Arcus announced a
clinical development collaboration with Strata Oncology utilizing
Strata’s precision drug development platform and proprietary biomarkers
to evaluate AB122 in a basket trial including tumor types that generally
have low levels of response to anti-PD-1 therapy. AB122 is also being
evaluated in an ongoing Phase 1 dose-escalation trial assessing
monotherapy dosing schedules. The Company expects AB122 to form the
backbone of many of its intra-portfolio combinations.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist, AB928, which is in a Phase 1/1b program
to evaluate AB928 in combination with other agents in multiple tumor
types, and an anti-PD-1 antibody, AB122, which is being evaluated in a
Phase 1 trial and is being tested in combination with Arcus’s other
product candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is being evaluated in a Phase 1 trial as monotherapy and
in combination with AB122, and AB680, a small-molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. Utilizing these unique
capabilities, Arcus has developed a robust and active early stage
discovery effort focused on small-molecule pipeline expansion. For more
information about Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190529005815/en/
Katherine Bock
(510) 694-6231
kbock@arcusbio.com
Nicole Arndt
(510) 284-4728
narndt@arcusbio.com
Source: Arcus Biosciences, Inc.